Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Verona Pharma plc (NASDAQ:VRNA ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush David Risinger - SVB Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Joon Lee - Truist Securities Operator Good morning.

Verona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:00 p.m.

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

Lead drug candidate had positive results in 2 Phase 3 trials. If its marketing application is submitted in a timely fashion, it should get reviewed and approved next year.

Buy Verona Pharma For Its Strong COPD Contender

Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trials show significant improvements in lung function, symptoms, and quality of life for COPD patients.

Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients

Ardelyx

Cabaletta Bio

89bio Inc

iShares Genomics Immunology and Healthcare ETF

Meihua International Medical Technologies Co

Biotech is all over the 52-week high leaderboard

Is This the Most Lucrative Way to Play AI?

Agios Pharmaceuticals

Veracyte

Adicet Bio, Inc.

Janux Therapeutics

OmniAb Inc

Sol-Gel Technologies

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.

7 Biotech Stocks That Could Be the Next Big Thing

Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis.

Verona Pharma: Strong Stock Growth Potential From A Promising New Drug

Verona Pharma plc (NASDAQ:VRNA ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush Joon Lee - Truist Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Operator Welcome to Verona Pharma's, Fourth Quarter and Full Year 2022 Financial Results and Operating Highlights Conference Call.

Verona Pharma plc (VRNA) Q4 2022 Earnings Call Transcript

Transformational results in Phase 3 ENHANCE program for COPD

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3 inhaled selective dual inhibitor of PDE3 and PDE4 targeting COPD, which is a $10Bn indication with a high unmet need.

Verona Pharma: Small Biotech Targeting $10Bn COPD Market With A Late Stage Drug

Verona Pharma plc's primary endpoint and all key secondary endpoints met in second phase 3 study known as ENHANCE-1; Ensifentrine was used to treat patients with chronic obstructive pulmonary disease. NDA filing of ensifentrine to the FDA for the treatment of patients with chronic obstructive pulmonary disease is expected in the 1st half of 2023, FDA approval possible in 2024.

Verona: Second Successful Phase 3 Moves The Needle Forward

Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD.

Verona Pharma: Breathing Deeply Could Bring Great Benefits

Ardmore Shipping

Engie SA

Hudson Technologies

Jackson Financial

MINISO Group Holding

Modine Manufacturing

Pinduoduo Inc - ADR

Super Micro Computer

Valero Energy

Expect the unexpected has been a common theme over the past two years as global economies and markets reel from a pandemic and the war in Ukraine. June 2022 posted some of the worst performance in decades, with the S&P 500 -21%, DJIA -15%, and trillions erased since 2021 peaks, including big names like Meta, Amazon, and Google.

Top 10 Stocks For 2023

Incyte

Inspire Medical Systems Inc

Madrigal Pharmaceuticals

Schrodinger 

Veeva Systems

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

AVEO Pharma

Wave Life Sciences

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

4 Drug Stocks That More Than Doubled This Year

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going

Bionano Genomics

GlaxoSmithKline

iCAD

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

Verona Pharma (NASDAQ: VRNA ) stock is rising higher on Tuesday after the company released results from a Phase 3 clinical trial. The big news here is the company's Phase 3 ENHANCE-1 trial meeting its primary endpoint.

Why Is Verona Pharma (VRNA) Stock Up 34% Today?

Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high. The post Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High appeared first on Investor's Business Daily.

Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High

U.S.-listed shares of Verona Pharma Plc VRNA, +2.74% rallied about 39% in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment for chronic obstructive pulmonary disease met the primary and secondary endpoints. The data "support our belief that ensifentrine will change the treatment paradigm for COPD," Verona CEO David Zaccardelli said in a news release.

News for Verona Pharma Stock (VRNA)